Cameroon has become the first country to launch a permanent non-trial Malaria vaccination program, following WHO approval.
It is an activity that started on Monday, January 22, 2024, in Cameroon, in a program aimed at eradicating Malaria in this country and on the African continent.
This vaccine is starting to be used, after the World Health Organization (WHO) approved the RTS, S vaccine, produced by the British pharmaceutical company GSK.
This vaccine is expected to reduce the number of children dying from malaria, which is a serious problem on the African continent.
Cameroon is the first country in Central Africa to start providing these vaccines, and there are more than 20 other countries that want to start this program this year, according to the International Organization for the Distribution of Vaccines (Gavi).
However, the British company that makes these vaccines (GSK) says that it has the capacity to make only 15 million doses per year, while at least 4 doses should be administered to each person, which protects them at a rate of only 30%.
